One shot to beat the flu? new drug peramivir tested in large trial
NCT ID NCT00486980
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a single injection of peramivir can safely treat uncomplicated flu in adults. Participants receive either 150 mg, 300 mg of peramivir, or a placebo, and researchers measure how quickly symptoms improve. The goal is to see if this antiviral shot offers a fast, effective option for flu relief.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- peramivir
- What this could lead to
- If effective, peramivir could offer a convenient single-dose treatment for flu, reducing symptom duration and severity.
- What could go wrong
- This is a phase 3 trial, but results may not confirm benefit over placebo, and side effects or lack of efficacy are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test
- New mRNA vaccine aims to outsmart flu by targeting its hidden parts